Analysts raised SVNT's 2014 revenue estimate to $63 mil today, from $57 mil ......After SVNT approx doubles Krystexxa's price next quarter SVNT will be profitable next yr and trade at around 4-5x sales or sport a $400-$500 mil market cap................... Best wishes to all.
SVNT is about to reprice their lead orphan drug Krystexxa to rare disease levels.....QCOR was also under $1/sh in early 2007-like SVNT presently is-before they did the same thing.....QCOR then sky-rocketed from $1/sh to $70/sh after further price raises, label expansion and new geographic market launches.....SVNT IMHO is QCOR in early 2007......Ugly, unloved, under $1/sh and about to rock-n-roll to $5-$8/sh by YE, depending on Dialysis study results......Have a good day.
S V N T........... is about to "soar" according to Cramer's website. SVNT is positioning itself for a sale. That's why they brought in Dr Meeker, ceo of GENZ, the largest orphan drug co in the world this yr . SVNT IMHO is worth about $5-$6/sh by YE, and possibly more if their pending Dialysis Study results mirror positive P3 Renal trial data. Congratulations again to all the old-time longs who held ONXX through thick and thin. SVNT is next. Good luck to all.